Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery

Trial ID or NCT#

NCT01245595

Status

not recruiting iconNOT RECRUITING

Purpose

Children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). Approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after the procedure. We currently have few medications to prevent this kidney injury. The hypothesis of this study is that giving aminophylline after heart surgery can decrease the acute kidney injury.

Official Title

A Randomized Placebo Controlled Trial of Aminophylline to Prevent Acute Kidney Injury in Children After Cardiac Surgery With Cardiopulmonary Bypass

Eligibility Criteria

Ages Eligible for Study: 1 Day to 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Less than 18 years old, undergoing cardiac surgery with bypass - neonates must be at least 36 weeks gestational age
Exclusion Criteria:
  1. - History of arrythmia or seizure, on extracorporeal membrane oxygenation (ECMO) support, already taking aminophylline/theophylline, liver failure, sepsis, on renal replacement therapy
View All Criteria
Show Less

Investigator(s)

Stephen J. Roth
David M. Axelrod, MD

Contact us to find out if this trial is right for you.

Contact

David M Axelrod, MD

View on ClinicalTrials.gov